JP2016117766A5 - - Google Patents

Download PDF

Info

Publication number
JP2016117766A5
JP2016117766A5 JP2016055140A JP2016055140A JP2016117766A5 JP 2016117766 A5 JP2016117766 A5 JP 2016117766A5 JP 2016055140 A JP2016055140 A JP 2016055140A JP 2016055140 A JP2016055140 A JP 2016055140A JP 2016117766 A5 JP2016117766 A5 JP 2016117766A5
Authority
JP
Japan
Prior art keywords
composition
light
molecule
mutant
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016055140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016117766A (ja
JP6113883B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016117766A publication Critical patent/JP2016117766A/ja
Publication of JP2016117766A5 publication Critical patent/JP2016117766A5/ja
Application granted granted Critical
Publication of JP6113883B2 publication Critical patent/JP6113883B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016055140A 2011-12-15 2016-03-18 受容体に対する親和性が増大した変異型light分子を使用する癌療法のための方法および組成物 Expired - Fee Related JP6113883B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576222P 2011-12-15 2011-12-15
US61/576,222 2011-12-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014547350A Division JP2015501839A (ja) 2011-12-15 2012-12-11 受容体に対する親和性が増大した変異型light分子を使用する癌療法のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2016117766A JP2016117766A (ja) 2016-06-30
JP2016117766A5 true JP2016117766A5 (https=) 2017-02-16
JP6113883B2 JP6113883B2 (ja) 2017-04-12

Family

ID=47436247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014547350A Pending JP2015501839A (ja) 2011-12-15 2012-12-11 受容体に対する親和性が増大した変異型light分子を使用する癌療法のための方法および組成物
JP2016055140A Expired - Fee Related JP6113883B2 (ja) 2011-12-15 2016-03-18 受容体に対する親和性が増大した変異型light分子を使用する癌療法のための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014547350A Pending JP2015501839A (ja) 2011-12-15 2012-12-11 受容体に対する親和性が増大した変異型light分子を使用する癌療法のための方法および組成物

Country Status (7)

Country Link
US (2) US9493532B2 (https=)
EP (1) EP2790730B1 (https=)
JP (2) JP2015501839A (https=)
CN (1) CN104284680A (https=)
AU (1) AU2012352454A1 (https=)
CA (1) CA2858876A1 (https=)
WO (1) WO2013090293A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858876A1 (en) 2011-12-15 2013-06-20 The University Of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
SG11201507883SA (en) 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
CN107921106B (zh) * 2015-05-20 2023-09-08 住友制药株式会社 Wt1抗原肽和免疫调节剂的组合用途
EP3349786A4 (en) * 2015-09-18 2019-04-10 The General Hospital Corporation d/b/a Massachusetts General Hospital COMPOSITIONS WITH ANTIFUGETACTIC PROPERTIES FOR THE TREATMENT OF CANCER
CN109195992A (zh) * 2016-04-29 2019-01-11 本康生物制药(深圳)有限公司 多特异性结合偶联物、相关的药物组合物及应用
EP3502142B1 (en) 2016-06-22 2021-10-27 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Bispecific antibody and antibody conjugate for tumour therapy and use thereof
CN106701825A (zh) * 2016-11-17 2017-05-24 中国科学院生物物理研究所 腺病毒疫苗Ad‑LIGHT‑HBsAg及其用于治疗慢性乙肝的用途
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
KR102762505B1 (ko) * 2017-02-17 2025-02-03 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 이식, 조직 재생, 장기형성 및 다중 조직 기능을 위한 부위로서의 지방-부속 림프 클러스터
KR102371420B1 (ko) * 2017-06-27 2022-03-08 (주)아모레퍼시픽 Tnfsf14 단백질을 포함하는 미백용 조성물
CA3112788A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
CN116426483B (zh) * 2021-12-30 2024-02-23 南京紫珑生物科技有限公司 Cd258蛋白在免疫治疗中的应用
EP4536692A1 (en) * 2022-06-08 2025-04-16 Gilead Sciences, Inc. Light muteins and uses thereof
CN116083435A (zh) * 2022-11-04 2023-05-09 吉林大学 以人源light截短型突变蛋白为基础的抗肿瘤的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE229810T1 (de) 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
WO2001079496A2 (en) 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
WO2005002628A1 (en) 2003-06-11 2005-01-13 The University Of Chicago Increased t-cell tumor infiltration by mutant light
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
EP2160200B1 (en) * 2007-05-14 2013-07-10 The University of Chicago Antibody-LIGHT fusion products as cancer therapeutics
WO2010051502A2 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
CA2858876A1 (en) 2011-12-15 2013-06-20 The University Of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors

Similar Documents

Publication Publication Date Title
JP2016117766A5 (https=)
WO2013090293A4 (en) Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
CN107849148B (zh) 三特异性结合蛋白质及使用方法
AU2014377106B2 (en) IL-15 heterodimeric protein and uses thereof
JP2022520998A5 (https=)
JP2017140051A5 (https=)
JP2015532102A5 (https=)
JP2022537824A5 (https=)
TW202003583A (zh) 抗muc1抗體
JP2023123649A5 (https=)
CN113330034A (zh) 针对B7-H3的IgV结构域的单克隆抗体及其用途
JP2022529943A5 (https=)
JP2017506217A5 (https=)
JP2007532139A5 (https=)
CN118251414A (zh) 延长释放免疫细胞衔接蛋白和治疗方法
JP2018512175A5 (https=)
JP2019531697A5 (https=)
JP2016156828A5 (https=)
JP2022513888A5 (https=)
JP2015530359A5 (https=)
JP2021533789A5 (https=)
CN111683687A (zh) 靶向edb的il-12组合物
EP4277707A1 (en) Interferon prodrugs and methods of making and using the same
JP2024521472A5 (https=)
WO2017107914A1 (zh) 一种药物设计方法和获得的药物及其应用